Alzheimer's Disease

The experimental drug lecanemab was able to slow down Alzheimer's in a large study. Many researchers think the drug will become the first to help large numbers of patients.

In a large study, the experimental Alzheimer's drug lecanemab reduced the rate of cognitive decline by 27 percent in people in the early stages of the disease.

Researchers are launching a make-or-break study to test the conventional wisdom about what causes Alzheimer's disease.

The lead author of a new study on the neurological impact of COVID-19 infection says that the disease "is not as benign" as people may think.

The promising study of the drug could reduce the cognitive effects of Alzheimer's disease.

For some people, a rare genetic mutation makes dementia inescapable. Three sisters have decided to confront fate with a genetic test and have joined a research project on possible treatments.

In stressful times, it's helpful to be reminded of the good people willing to help out. That's the theme of a new podcast from the team at Hidden Brain. It's called: My Unsung Hero.

Microglia are amoeba-like cells that scour the brain for injuries and invaders. But sometimes the usually helpful cells go into overdrive and damage the brain, researchers say.

Aduhelm is the first treatment approved in the country to slow cognitive decline in those living with Alzheimer's. Doctors have refused to prescribe it, given the lack of data and evidence behind it.

Scientists have created detailed maps of the brain area that controls movement in mice, monkeys and people. The maps could help explain human ailments like Alzheimer's and Lou Gehrig's disease.